Aligos Therapeutics (ALGS) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ALGS Stock Alerts $0.69 +0.03 (+4.56%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 8:26 PM | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)May 13, 2024 | marketbeat.comAligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 27.6% in AprilAligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 838,500 shares, a growth of 27.6% from the April 15th total of 657,200 shares. Based on an average trading volume of 388,000 shares, the days-to-cover ratio is currently 2.2 days.May 11, 2024 | americanbankingnews.comAligos Therapeutics, Inc. (NASDAQ:ALGS) to Post Q2 2024 Earnings of ($0.16) Per Share, Leerink Partnrs ForecastsMay 10, 2024 | marketbeat.comLeerink Partnrs Weighs in on Aligos Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ALGS)Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Analysts at Leerink Partnrs increased their Q2 2024 earnings per share (EPS) estimates for Aligos Therapeutics in a report issued on Tuesday, May 7th. Leerink Partnrs analyst R. Ruiz now expects that the company will post earnings per shareMay 10, 2024 | markets.businessinsider.comHold Rating on Aligos Therapeutics Amidst Clinical Trials and Financial StabilityMay 9, 2024 | finance.yahoo.comAligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)May 7, 2024 | investorplace.comALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsMay 1, 2024 | marketbeat.comAligos Therapeutics (ALGS) Set to Announce Quarterly Earnings on TuesdayAligos Therapeutics (NASDAQ:ALGS) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.April 30, 2024 | finance.yahoo.comAligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024April 27, 2024 | marketbeat.comShort Interest in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Decreases By 24.4%Aligos Therapeutics, Inc. (NASDAQ:ALGS - Get Free Report) saw a significant decrease in short interest in April. As of April 15th, there was short interest totalling 657,200 shares, a decrease of 24.4% from the March 31st total of 868,800 shares. Based on an average daily volume of 388,300 shares, the short-interest ratio is presently 1.7 days.April 25, 2024 | globenewswire.comAligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyApril 25, 2024 | finance.yahoo.comAligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDApril 9, 2024 | finance.yahoo.comAligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024April 3, 2024 | finance.yahoo.comAligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsMarch 27, 2024 | globenewswire.comAligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 StudiesMarch 16, 2024 | uk.investing.comAligos Therapeutics Inc (ALGS)March 15, 2024 | markets.businessinsider.comMaintaining a Hold: Balancing Promise and Risk in Aligos Therapeutics’ Clinical PipelineMarch 14, 2024 | finance.yahoo.comAligos Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2024 | benzinga.comRecap: Aligos Therapeutics Q4 EarningsMarch 12, 2024 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | globenewswire.comAligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial ResultsMarch 8, 2024 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Aligos Therapeutics (ALGS)March 6, 2024 | seekingalpha.comTracking Baker Brothers Portfolio - Q4 2023 UpdateMarch 6, 2024 | marketbeat.comAligos Therapeutics (ALGS) Set to Announce Earnings on TuesdayAligos Therapeutics (NASDAQ:ALGS) will be releasing earnings after the market closes on Tuesday, March 12, Zacks reports.March 5, 2024 | globenewswire.comAligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024February 26, 2024 | globenewswire.comAligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024February 24, 2024 | msn.comAligos Therapeutics (ALGS) Price Target Increased by 300.00% to 4.08February 23, 2024 | benzinga.comAligos Therapeutics Stock (NASDAQ:ALGS) Earnings Dates and Earning CallsFebruary 23, 2024 | benzinga.comAligos Therapeutics Stock (NASDAQ:ALGS), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comAligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024February 20, 2024 | globenewswire.comAligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024February 19, 2024 | finance.yahoo.comAligos Therapeutics, Inc. (ALGS)February 15, 2024 | investing.comAligos Therapeutics bolsters executive team with new VPsFebruary 13, 2024 | finance.yahoo.comAligos Therapeutics Strengthens Finance Leadership Team with Two New AppointmentsFebruary 10, 2024 | msn.comAligos Therapeutics in portfolio reorganization focused on NASH, COVID assetsFebruary 7, 2024 | marketbeat.comLeerink Partnrs Comments on Aligos Therapeutics, Inc.'s FY2028 Earnings (NASDAQ:ALGS)Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) - Equities researchers at Leerink Partnrs issued their FY2028 earnings estimates for Aligos Therapeutics in a note issued to investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings ofJanuary 26, 2024 | msn.comAligos Therapeutics Launches Voluntary Option Exchange ProgramJanuary 5, 2024 | morningstar.comAligos Therapeutics Inc Ordinary SharesJanuary 5, 2024 | finance.yahoo.comIs Aligos Therapeutics (ALGS) Stock Outpacing Its Medical Peers This Year?December 7, 2023 | finance.yahoo.comAligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)November 20, 2023 | finance.yahoo.comAligos Therapeutics To Present at the Piper Sandler Healthcare ConferenceNovember 17, 2023 | msn.comAligos Therapeutics files to sell 168.73M shares of common stockNovember 13, 2023 | finance.yahoo.comAligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit ProfileNovember 10, 2023 | finance.yahoo.comAligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)November 3, 2023 | finance.yahoo.comAligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker DataNovember 2, 2023 | markets.businessinsider.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comAligos Therapeutics Inc (ALGS) Reports Q3 2023 Financial Results and Business Progress Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this small stock before coming AI Tidal Wave (Ad)The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture. Get the name and ticker symbol for free - just click here. ALGS Media Mentions By Week ALGS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALGS News Sentiment▼0.410.43▲Average Medical News Sentiment ALGS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALGS Articles This Week▼31▲ALGS Articles Average Week Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LENZ Therapeutics News Today AVROBIO News Today Genenta Science News Today IN8bio News Today Cidara Therapeutics News Today Dyadic International News Today OKYO Pharma News Today Cyclo Therapeutics News Today Ikena Oncology News Today Quince Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALGS) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry ResearchClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
